Company Description
Aspargo is a commercial stage specialty pharmaceutical and med-tech company focused on designing, developing and marketing proprietary, oral liquid suspension formulations of leading oral solid dose prescription and over-the-counter medications dispensed through “smart”, digitally connected, container closure drug delivery systems and associated mobile apps.
Our first commercial product, Sildenafil Oral Suspension, indicated for the treatment of erectile dysfunction (ED), is an oral liquid suspension formulation of sildenafil citrate, administered through a metered dose container closure system consisting of a 30 ml bottle and mechanical pump.
We market Sildenafil Oral Suspension in Spain under the brand name, BANDOL®, and in Germany and the United Kingdom under the brand name, HEZKUE®.
Sildenafil Oral Suspension is approved for sale in multiple countries in the European Union (EU) and is undergoing the approval process in the United States.
| Country | United States |
| Founded | 2019 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Michael Demurjian |
Contact Details
Address: 17 State Street, Suite 3220 New York, NY 10004 United States | |
| Phone | (646) 503-1260 |
| Website | aspargolabs.com |
Stock Details
| Ticker Symbol | AAGO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001805092 |
| Employer ID | 84-3757833 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Demurjian | Chief Executive Officer, Chairman and Director |
| Harold D. Tamayo, MBA | Chief Financial Officer |
| Mario Guralnik, Ph.D. | Chief Regulatory Officer |
| Andrew J. Chamlin | Chief Marketing Officer |
| Steven Kaplan, M.D. | Chief Medical Officer and Director Nominee; Chairman of Medical Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 10, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 13, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 7, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 14, 2024 | DRS | [Cover] Draft Registration Statement |
| Dec 5, 2022 | D | Notice of Exempt Offering of Securities |
| Mar 28, 2022 | D | Notice of Exempt Offering of Securities |
| Oct 15, 2020 | D/A | Filing |
| Jul 28, 2020 | D/A | Filing |
| Mar 3, 2020 | D | Notice of Exempt Offering of Securities |